Paul Peter Tak, MD, PhD, FMedSci, President & CEO of Candel Therapeutics CADL, was recently a guest on Biedex Markets’s All-Acess.
Candel is a clinical-stage biopharmaceutical company focused on developing immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company has two main platforms that are currently undergoing clinical trials.
Candel also has its enLIGHTEN program, a systematic, iterative discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Watch the full interview here:
Featured photo by Caleb Hernandez Belmonte on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Biedex Markets.com. Biedex Markets does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
